Technical Analysis for QURE - uniQure N.V.

Grade Last Price % Change Price Change
D 5.78 -1.11% -0.07
QURE closed down 1.11 percent on Friday, November 22, 2024, on 66 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to bounce off of its 200 day moving average, an important long-term support line. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Flat Down Down

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
200 DMA Support Bullish 0.00%
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Centerline Cross Bearish -1.11%
Crossed Above 200 DMA Bullish -1.11%
Stochastic Reached Oversold Weakness -1.11%
Wide Bands Range Expansion -1.11%
Oversold Stochastic Weakness -1.11%

   Recent Intraday Alerts

Alert Time
200 DMA Support about 13 hours ago
Down 2 % about 13 hours ago
Fell Below 200 DMA about 13 hours ago
Possible NR7 about 14 hours ago
Down 1% about 17 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

uniQure N.V. Description

uniQure BV, a biopharmaceutical company, develops gene therapies through its modular technology platform for the treatment of genetic or acquired diseases. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency, an orphan metabolic disease. It also develops a pipeline of additional adeno-associated virus (AAV) based gene therapies, including AMT-060, a gene therapy for the treatment of hemophilia B; AMT-021 for acute intermittent porphyria; AMT-110 for Sanfilippo B syndrome; and AAV2/glial cell line-derived neurotrophic factor for Parkinson's disease, as well as various programs that are in early preclinical development stage. The company has collaborations with Chiesi Farmaceutici S.p.A., Digna Biotech, Institut Pasteur, and University of California San Francisco. uniQure BV was founded in 1998 and is headquartered in Amsterdam, the Netherlands.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Disease Clinical Development Gene Therapy Genetics Parkinson's Disease Metabolic Disease Applied Genetics Gene Delivery Lipoprotein Hemophilia Adeno Associated Virus Treatment Of Hemophilia Acute Intermittent Porphyria Alipogene Tiparvovec Glybera Lipase Lipoprotein Lipase Deficiency

Is QURE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 11.35
52 Week Low 3.73
Average Volume 780,184
200-Day Moving Average 5.75
50-Day Moving Average 5.93
20-Day Moving Average 6.42
10-Day Moving Average 6.35
Average True Range 0.51
RSI (14) 43.18
ADX 19.09
+DI 21.81
-DI 28.39
Chandelier Exit (Long, 3 ATRs) 6.43
Chandelier Exit (Short, 3 ATRs) 6.88
Upper Bollinger Bands 7.75
Lower Bollinger Band 5.10
Percent B (%b) 0.26
BandWidth 41.33
MACD Line -0.05
MACD Signal Line 0.11
MACD Histogram -0.1596
Fundamentals Value
Market Cap 276.35 Million
Num Shares 47.8 Million
EPS -4.79
Price-to-Earnings (P/E) Ratio -1.21
Price-to-Sales 2.53
Price-to-Book 1.05
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.19
Resistance 3 (R3) 6.21 6.10 6.12
Resistance 2 (R2) 6.10 5.99 6.09 6.10
Resistance 1 (R1) 5.94 5.93 5.88 5.92 6.08
Pivot Point 5.82 5.82 5.79 5.81 5.82
Support 1 (S1) 5.66 5.72 5.61 5.64 5.48
Support 2 (S2) 5.55 5.65 5.54 5.46
Support 3 (S3) 5.39 5.55 5.44
Support 4 (S4) 5.37